PAVM News and Press, PAVmed Inc. From 06/22/21

Shares of PAVmed Inc. (NASDAQ:PAVM) traded at a new 52-week high today of $6.69. So far today approximately 277,000 shares have been exchanged, as compared to an average 30-day volume of 2.2 million shares. Over the past year, PAVmed Inc. has traded in a range of $1.63 to $6.69 and is no...

PAVmed Inc. (NASDAQ:PAVM) traded today at a new 52-week high of $6.63. So far today approximately 277,000 shares have been exchanged, as compared to an average 30-day volume of 2.5 million shares. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technolog...

PAVmed's main commercial-stage product, EsoCheck/EsoGuard, is a life-saving product addressing a $25bil market and is supported by Exact Sciences founder Stanley Lapidus. PAVmed's second commercial-stage product, CarpX, is a minimally invasive tool to conduct carpel tunnel surgery and...

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the appointment of prominent global technology ind...

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its major subsidiary, Lucid Diagnostics Inc. (“Lucid”), has comple...

PAVmed ([[PAVM]] +2.1%) launched a new subsidiary, digital health company Veris Health, which acquired digital health company Oncodisc which has groundbreaking tools to improve personalized cancer care through remote patient monitoring."PAVmed is entering the rapidly expanding ...

New subsidiary Veris acquires privately held oncology digital health company Oncodisc Inc. Technologies include first intelligent implantable vascular access port with biologic sensors and wireless communication combined with rem...

According to Stock Traders Daily, a 20-year industry veteran, #investors can use the #priceaction in Pavmed Inc. Common Stock (NASDAQ: PAVM) to foretell upcoming changes. A current example is provided below.  There are trading plans for PAVM, but the data on this page does ...

PAVmed ([[PAVM]] -1.1%) and its major subsidiary Lucid Diagnostics announce that Lucid’s EsoCheck Esophageal Cell Collection Device with Collect + Protect technology has received CE Mark certification. With this certification, EsoCheck may now be marketed in CE Mark Euro...

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that Lucid&#x...